AstraZeneca PLC (AZN)vsGE HealthCare Technologies Inc. (GEHC)
AZN
AstraZeneca PLC
$160.17
+2.23%
HEALTHCARE · Cap: $252.33B
GEHC
GE HealthCare Technologies Inc.
$63.93
-0.48%
HEALTHCARE · Cap: $30.38B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 189% more annual revenue ($61.37B vs $21.27B). AZN leads profitability with a 17.0% profit margin vs 9.3%. AZN appears more attractively valued with a PEG of 1.28. GEHC earns a higher WallStSmart Score of 65/100 (C+).
AZN
Buy60
out of 100
Grade: C+
GEHC
Buy65
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+18.4%
Fair Value
$196.10
Current Price
$160.17
$35.93 discount
Intrinsic value data unavailable for GEHC.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 21 in profit
Strong operational efficiency at 23.5%
Generating 2.1B in free cash flow
Attractively priced relative to earnings
Reasonable price relative to book value
Areas to Watch
2.5% earnings growth
Distress zone — elevated risk
Expensive relative to growth rate
Weak financial health signals
Negative free cash flow — burning cash
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.0% and operating margin at 23.5%. PEG of 1.28 suggests the stock is reasonably priced for its growth.
Bull Case : GEHC
The strongest argument for GEHC centers on P/E Ratio, Price/Book.
Bear Case : AZN
The primary concerns for AZN are EPS Growth, Altman Z-Score.
Bear Case : GEHC
The primary concerns for GEHC are PEG Ratio, Piotroski F-Score, Free Cash Flow.
Key Dynamics to Monitor
AZN profiles as a mature stock while GEHC is a value play — different risk/reward profiles.
GEHC carries more volatility with a beta of 0.82 — expect wider price swings.
AZN is growing revenue faster at 6.4% — sustainability is the question.
AZN generates stronger free cash flow (2.1B), providing more financial flexibility.
Bottom Line
GEHC scores higher overall (65/100 vs 60/100). AZN offers better value entry with a 18.4% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
GE HealthCare Technologies Inc.
HEALTHCARE · MEDICAL DEVICES · USA
GE HealthCare Technologies Inc. provides medical technology, pharmaceutical diagnostics, and digital solutions in the United States. The company is headquartered in Chicago, Illinois.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?